We have located links that may give you full text access.
Anti-Rh32 causing severe hemolytic disease of the newborn.
Revue Française de Transfusion et Immuno-hématologie 1984 October
A case of severe hemolytic disease of the newborn due to anti-Rh32 (R = N) is described. The infant recovered without any evidence of neurologic defects, following one exchange transfusion and phototherapy. Using commercial antisera, very weak reactions with anti-Rh2(C) and apparently normal reactions with anti-Rh5(e) were found in the family members carrying the R = N gene complex. However titrations with individual antisera revealed a weakened expression of the Rh5(e) antigen, albeit to a lesser extent than the Rh2(C). It is felt that the serologic findings are due to the fact that the R = N haplotype was paired with an Rh gene carrying normal amounts of Rh4(c) and Rh5(e) antigens. In addition, the maternal anti-Rh32 appears to be pure.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app